<DOC>
	<DOCNO>NCT01149694</DOCNO>
	<brief_summary>This first-in-man study novel investigational botanical drug complex , PUR 0110 rectal enema , show potent anti-inflammatory , antioxidant immunomodulatory effect follow vitro vivo pharmacology study , assess safety tolerability sequential single-ascending dos normal healthy volunteer determine maximum tolerate dose ( MTD ) . As tertiary objective , study also investigate presence specific pharmacokinetic marker follow administration single-dose PUR 0110 dose level . The study design single-center , randomize , double-blind , parallel-group , sequential single-ascending dose , placebo-controlled safety , tolerability pharmacokinetic study PUR 0110 rectal enema 24 normal healthy male volunteer . Eligible subject randomly assign 4 Cohorts 6 subject receive active drug ( PUR 0110 Enema ) placebo enema follow : 187.5 mg/60 g - Cohort 1 , 375 mg/60 g - Cohort 2 , 750 mg/60 g - Cohort 3 1500 mg/60 g - Cohort 4 . Within Cohort , subject randomized 2:1 ratio receive either active treatment ( PUR 0110 enema ; n = 4 ) placebo enema ( n = 2 ) . Each subject receive 1 dose assign study medication dose subject within cohort also sequential inclusion .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability PUR 0110 Rectal Enema Normal Healthy Volunteers</brief_title>
	<detailed_description>Flexible sigmoidoscopy perform Screening Period within 72 48 hour pre-dose within 9 +/- 1 hour post-dosing visually examine colonic mucosa sign local toxicity grade normal/abnormal ; 3 pinch biopsy obtain endoscopy level colon ( &lt; 50 cm anal verge ) histology . At baseline flexible sigmoidoscopy , subject must normal colonic rectal mucosa ( i.e. , bleed , inflammation , edema , ulceration abnormal finding ) include study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Healthy adult nonsmoking male volunteer age 18 55 year , inclusive . Must provide voluntary write informed consent prior initiation screening , must capable follow verbal write study instruction , able commit confinement return visit entire period study . Must body mass index ( BMI ) within 18 30 kg/m2 BMI Chart . Must normal digital rectal examination screening . Must normal colonic rectal mucosa baseline flexible sigmoidoscopy ( i.e. , bleed , inflammation , edema , ulceration abnormal finding ) . Must clinically significant abnormal finding medical history , physical examination clinical laboratory test result . History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatological , neurological , psychiatric disease . History allergic reaction hypersensitivity spinach , spinach tablet , spinach powder spinach extract ; latex , mold mushroom . Subjects abnormal digital rectal examination screen Subjects abnormal colonic rectal mucosa baseline flexible sigmoidoscopy i.e. , bleeding , inflammation , edema ulceration abnormal finding . Subjects use NSAIDs within 14 day prior dose . History pseudoallergic hypersensitivity food color additive , tartrazine ( E102 ) sunset yellow ( E110 ) , allergic asthma , aspirin intolerance , severe multiple allergy . History gout , pseudogout hyperuricemia . History kidney stone . Past medical history significant colonic surgery , except benign polyp removal . Subjects anatomical abnormality colon , e.g. , short bowel abnormality . Subjects history rectal bleeding , passage mucus rectally , irregular bowel habit , e.g. , frequent diarrhea constipation . Subjects internal external hemorrhoid . History presence alcoholism drug abuse within past 2 year . Subjects current history smoking . If former smoker , must stop smoke least 3 month qualify study entry . Subjects test positive screening HIV , HbsAg HCV . Subjects use prescription medication within 14 day prior dose . Subjects use rectal enema laxative within 7 day prior dose . Subjects use overthecounter ( OTC ) medication within 7 day prior dose . Subjects make donation blood blood product ( exception plasma note ) within 56 day prior dose . Subjects make plasma donation within 7 day prior dose . Subjects hemoglobin less 14.0 g/dl . Subjects participate another clinical trial within 28 day prior dose .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>PurGenesis Technologies Inc .</keyword>
	<keyword>PUR 0110 rectal enema</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Distal</keyword>
	<keyword>Normal healthy volunteer</keyword>
</DOC>